Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (IgG(L)-scFv) (IGLFV-136)

Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (IgG(L)-scFv) is formed by an IgG and two scFv moieties. The scFv fragments from an anti-CEA antibody are fused to the C terminus of an anti-DR5 IgG light (L) chains, or vice versa. It is a type of appended IgGs, which is bispecific and tetravalent (2+2 antigen-binding valency). This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CEA & DR5

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Breast cancer; Ovary cancer; Colon cancer; Lung cancer

Targets

Target 1

CEA

Gene ID

1048

UniProt ID

A0A024R0K5

Alternative Names

CEACAM5; carcinoembryonic antigen; carcinoembryonic antigen related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100

Target 2

DR5

Gene ID

8795

UniProt ID

O14763

Alternative Names

DR5; Death Receptor 5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5; Tumor necrosis factor receptor superfamily member 10B; TNFRSF10B

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (IgG(L)-scFv) (IGLFV-136). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (IgG(L)-scFv) (CAT#: IGLFV-136)

Specifications

Targets

Customer Reviews and Q&As